A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

• Asıl Yazarlar: Yuji Orito (Yazar), Naoyuki Otani (Yazar), Yuki Matsumoto (Yazar), Katsukuni Fujimoto (Yazar), Nobuyuki Oshima (Yazar), Brian M. Maas (Yazar), Luzelena Caro (Yazar), Antonios O. Aliprantis (Yazar), Kara S. Cox (Yazar), Osamu Tokumaru (Yazar), Masaaki Kodama (Yazar), Hideo Kudo (Yazar), Hiromitsu Imai (Yazar), Naoto Uemura (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2022-07-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among all infants worldwide and remains a significant cause of morbidity and mortality. To address this unmet medical need, MK‐1654, a half‐life extended RSV neutralizing monoclonal antibody, is in c...